Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447) Meeting Abstract
| Authors: | Shah, M. A.; Ramanathan, R. K.; Ilson, D.; Randazzo, J.; Schwartz, G. K.; Tse, A.; D'adamo, D.; Levner, A.; Capanu, M.; Kelsen, D. P. |
| Abstract Title: | Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447) |
| Meeting Title: | 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 24 |
| Issue: | 18 Suppl. Pt. 1 |
| Meeting Dates: | 2006 Jun 2-6 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2006-06-01 |
| Start Page: | 183S |
| Language: | English |
| ACCESSION: | WOS:000239009401167 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2006.24.18_suppl.4020 |
| Notes: | --- - Meeting Abstract: 4020 - 42nd Annual Meeting of the American-Society-of-Clinical-Oncology - JUN 02-06, 2006 - Atlanta, GA - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
